Half-year report · HY
4574.TEDINET S100YVYD
Period2026-01-01 → 2026-06-30
Filed2026-08-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.6bn | 2026-01-01 → 2026-06-30 | Cons. | Net sales |
| Revenue | ¥6.4bn | 2025-01-01 → 2025-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.4bn | 2025-01-01 → 2025-06-30 | Cons. | Net sales |
| Operating income | ¥17m | 2026-01-01 → 2026-06-30 | Cons. | Operating income |
| Operating income | ¥46m | 2025-01-01 → 2025-06-30 | Cons. | Operating income |
| Ordinary income | ¥41m | 2026-01-01 → 2026-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥482m | 2025-01-01 → 2025-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥20m | 2025-01-01 → 2025-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥40m | 2026-01-01 → 2026-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥382m | 2025-01-01 → 2025-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥44m | 2026-01-01 → 2026-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥923m | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥279m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥44m | 2026-01-01 → 2026-06-30 | Cons. | Profit loss |
| Net income | ¥279m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss |
| Total assets | ¥11.1bn | at 2026-06-30 | Cons. | Assets |
| Total assets | ¥12.3bn | at 2025-12-31 | Cons. | Assets |
| Total assets | ¥11.7bn | at 2025-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥2.7bn | at 2026-06-30 | Cons. | Liabilities |
| Total liabilities | ¥3.8bn | at 2025-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥8.4bn | at 2026-06-30 | Cons. | Net assets |
| Net assets / equity | ¥8.5bn | at 2025-12-31 | Cons. | Net assets |
| Net assets / equity | ¥7.9bn | at 2025-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.7bn | at 2026-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.3bn | at 2025-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.7bn | at 2026-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.3bn | at 2025-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.1bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.5bn | at 2024-12-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥66m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥814m | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥61m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥685m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥142m | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥295m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥853m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.2bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥684m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥0.89 | 2026-01-01 → 2026-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥169.51 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥5.57 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 76.0% | at 2026-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.4% | at 2025-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.1% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2026-01-01 → 2026-06-30 | ¥2m |
| Otherother segments | revenue external | 2026-01-01 → 2026-06-30 | ¥2m |
| Otherother segments | segment profit | 2026-01-01 → 2026-06-30 | −¥14m |
| Reconciling Itemsreconciling | segment profit | 2026-01-01 → 2026-06-30 | −¥433m |
| Infection Control Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥111m |
| Infection Control Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥111m |
| Infection Control Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | −¥92m |
| Pharmaceuticals Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥2.5bn |
| Pharmaceuticals Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥2.5bn |
| Pharmaceuticals Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥557m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2026-01-01 → 2026-06-30 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2026-01-01 → 2026-06-30 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2026-01-01 → 2026-06-30 | ¥450m |
| Otherother segments | revenue | 2025-01-01 → 2025-06-30 | ¥2m |
| Otherother segments | revenue external | 2025-01-01 → 2025-06-30 | ¥2m |
| Otherother segments | segment profit | 2025-01-01 → 2025-06-30 | −¥7m |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-06-30 | −¥396m |
| Infection Control Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥203m |
| Infection Control Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥203m |
| Infection Control Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥151m |
| Pharmaceuticals Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥2.2bn |
| Pharmaceuticals Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥2.2bn |
| Pharmaceuticals Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥601m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-01-01 → 2025-06-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-01-01 → 2025-06-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-01-01 → 2025-06-30 | ¥443m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 499
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | InterimInstant_No2MajorShareholdersMember | 3350633 | |
| Shareholding ratio | InterimInstant_No2MajorShareholdersMember | 0.0666 | |
| Number of shares held | InterimInstant_No3MajorShareholdersMember | 3312278 | |
| Shareholding ratio | InterimInstant_No3MajorShareholdersMember | 0.0658 | |
| Number of shares held | InterimInstant_No4MajorShareholdersMember | 3185900 | |
| Shareholding ratio | InterimInstant_No4MajorShareholdersMember | 0.0633 | |
| Number of shares held | InterimInstant_No5MajorShareholdersMember | 3101900 | |
| Shareholding ratio | InterimInstant_No5MajorShareholdersMember | 0.0617 | |
| Number of shares held | InterimInstant_No6MajorShareholdersMember | 2129400 | |
| Shareholding ratio | InterimInstant_No6MajorShareholdersMember | 0.0423 | |
| Number of shares held | InterimInstant_No7MajorShareholdersMember | 1900791 | |
| Shareholding ratio | InterimInstant_No7MajorShareholdersMember | 0.0378 | |
| Number of shares held | InterimInstant_No8MajorShareholdersMember | 1508000 | |
| Shareholding ratio | InterimInstant_No8MajorShareholdersMember | 0.0300 | |
| Number of shares held | InterimInstant_No9MajorShareholdersMember | 1337737 | |
| Shareholding ratio | InterimInstant_No9MajorShareholdersMember | 0.0266 | |
| Number of shares held | InterimInstant_No10MajorShareholdersMember | 1311400 | |
| Shareholding ratio | InterimInstant_No10MajorShareholdersMember | 0.0261 | |
| Number of shares held | InterimInstant | 25041504 | |
| Shareholding ratio | InterimInstant | 0.4978 | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 328800 | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 50285300 | |
| Number of voting rights issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 502853 | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesLessThanOneUnitMember | 22800 | |
| Number of shares issued shares voting rights | InterimInstant | 50636900 | |
| Number of voting rights issued shares voting rights | InterimInstant | 502853 | |
| Number of shares held in own name treasury shares etc | InterimInstant_Row1Member | 328800 | |
| Number of shares held in others names treasury shares etc | InterimInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | InterimInstant_Row1Member | 328800 | |
| Shareholding ratio treasury shares etc | InterimInstant_Row1Member | 0.0065 | |
| Number of shares held in own name treasury shares etc | InterimInstant | 328800 | |
| Number of shares held in others names treasury shares etc | InterimInstant | － | |
| Total number of shares held treasury shares etc | InterimInstant | 328800 | |
| Shareholding ratio treasury shares etc | InterimInstant | 0.0065 | |
| Cash and deposits | Prior1YearInstant | 4256000000 | JPY |
| Cash and deposits | InterimInstant | 2666000000 | JPY |
| Electronically recorded monetary claims operating ca | Prior1YearInstant | 1000000 | JPY |
| Electronically recorded monetary claims operating ca | InterimInstant | 0 | JPY |
| Accounts receivable trade | Prior1YearInstant | 2449000000 | JPY |
| Accounts receivable trade | InterimInstant | 1934000000 | JPY |
| Short term investment securities | Prior1YearInstant | － | JPY |
| Short term investment securities | InterimInstant | 500000000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 309000000 | JPY |
| Merchandise and finished goods | InterimInstant | 459000000 | JPY |
| Work in process | Prior1YearInstant | 801000000 | JPY |
| Work in process | InterimInstant | 868000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |